A deluge of data for various COVID-19 vaccine candidates is expected in the next month or two, and today’s article notes that strategists at Goldman Sachs believe that this “vaccine outlook will ultimately dwarf the election in terms of market impact.” How are investors bracing for impending test results from vaccine front-runners – and what impact could encouraging or disappointing efficacy results have on both vaccine makers and the broader market? CLICK HERE.